## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($191.75)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Safety Syringes Market Is Going to Boom |• BD (Becton Dickinson and Company) • Covidien (Medtronic)**
- Source: openPR.com | 20251216T090732 | Bullish | Relevance: 100%
- Worldwide Market Reports (WMR) predicts substantial growth for the "Safety Syringes Market" in the coming years, offering a comprehensive analysis of market dynamics, drivers, and regional insights. The report includes an enhanced 2032 Edition with updated data, competitive landscape analysis of key players like BD and Medtronic, and outlines segmental highlights by types and applications. It emphasizes robust research methodology and aims to provide actionable intelligence for business growth and investment decisions.

**2. BD Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec**
- Source: Becton Dickinson | 20251215T220835 | Bullish | Relevance: 100%
- BD (Becton, Dickinson and Company) announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics offerings in Europe. This expansion follows the In Vitro Diagnostic Medical Device Regulation (IVDR) certification of two VIASURE assays, developed by Certest Biotec, for use on the BD MAX™ System. These new assays provide clinical laboratories with the ability to quickly and accurately detect a broad range of pathogens using a fully automated molecular platform.

**3. Cardinal Capital Management Inc. Grows Holdings in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251216T104249 | Neutral | Relevance: 100%
- Cardinal Capital Management Inc. increased its stake in Becton, Dickinson and Company by 4.4% to 143,928 shares, valued at approximately $26.94 million. Institutional ownership of BDX is high at 86.97%, with major firms also increasing their positions. Analysts have a mixed view with a "Hold" consensus rating and an average target price of $204.91, while the company recently raised its quarterly dividend to $1.05 per share.

**4. Becton, Dickinson and Company Expands BD Max System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec**
- Source: www.marketscreener.com | 20251215T220814 | Bullish | Relevance: 100%
- Becton, Dickinson and Company (BD) announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics offerings in Europe. This expansion follows IVDR certification of two VIASURE assays, developed by Certest Biotec, for use on the BD MAX System. The new assays enable clinical laboratories to quickly and accurately detect a broad range of pathogens using an automated molecular platform.

**5. BD Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec**
- Source: PR Newswire | 20251215T214152 | Bullish | Relevance: 100%
- BD (Becton, Dickinson and Company) has expanded its respiratory and sexually transmitted infection (STI) diagnostics options in Europe. This expansion follows IVDR certification of two VIASURE assays developed by Certest Biotec for use on the BD MAX™ System, allowing for broad pathogen detection using a fully automated molecular platform. The new assays enable rapid and accurate detection of multiple respiratory viruses and STIs, providing timely information for treatment decisions.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +7.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (1 raises, avg +7%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $57.4B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 12.6 |
| Current P/E | 13.4 |
| YoY Growth | 6.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.3% to 4.0% (+7.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.0pp (needs >4.0% for momentum thesis). MRS_5 at 2.8% confirms short-term momentum alignment. AM_20 at 3.7% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.72), confirming momentum. OFD pattern: -SBH (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.97% (CS: 69) | Neutral |
| RSI_14 | 63.3 | Neutral |
| MACD Histogram | 0.72 | Bullish |
| vs SMA20 | 1.033x | Above |
| vs SMA50 | 1.059x | Above |
| vs SMA200 | 1.051x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $200.09
- **Stop Loss:** $191.75 (4.2% risk)
- **Target:** $216.77 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 143
- **Position Value:** $28,612.87
- **Portfolio %:** 28.61%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*